EP1364664A1 - Procédé de revêtement d'une prothèses endovasculaires avec une couche de polysaccharides et prothèses obtenues par un tel procédé - Google Patents

Procédé de revêtement d'une prothèses endovasculaires avec une couche de polysaccharides et prothèses obtenues par un tel procédé Download PDF

Info

Publication number
EP1364664A1
EP1364664A1 EP20030090138 EP03090138A EP1364664A1 EP 1364664 A1 EP1364664 A1 EP 1364664A1 EP 20030090138 EP20030090138 EP 20030090138 EP 03090138 A EP03090138 A EP 03090138A EP 1364664 A1 EP1364664 A1 EP 1364664A1
Authority
EP
European Patent Office
Prior art keywords
layer
hyaluronic acid
stent
cross
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20030090138
Other languages
German (de)
English (en)
Inventor
Gerd Bayer
Markus Nagel
Alexander Borck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotronik SE and Co KG
Original Assignee
Biotronik Mess und Therapiegeraete GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotronik Mess und Therapiegeraete GmbH and Co filed Critical Biotronik Mess und Therapiegeraete GmbH and Co
Publication of EP1364664A1 publication Critical patent/EP1364664A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00Materials or methods for coatings medical devices
    • A61L2420/02Methods for coating medical devices
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/90Stent for heart valve
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/901Method of manufacturing prosthetic device
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31536Including interfacial reaction product of adjacent layers

Definitions

  • the invention relates to methods for coating stents, in particular cardiovascular implants with a polysaccharide layer or Polysaccharide derivative layer and manufactured by these processes Stents.
  • polysaccharides as are known to be biocompatible. Typical representatives are in this context Heparin, chitosan, alginate or hyaluronic acid. The latter have on the one hand it has proven to be very well tolerated by the body, and on the other hand, coatings made of hyaluronic acid hydrophilic and consequently those provided with it Devices easy to implant.
  • US-A-4,957,744 relates to cross-linked esters of hyaluronic acid which for various medical and cosmetic articles as well as pharmaceutical Compositions are used.
  • the networked esters result from the esterification of polyhydric alcohols with two or more carboxy groups of hyaluronic acid.
  • Such cross-linked esters are especially in the field of bioabsorbable plastics for medical and surgical items can be used.
  • WO 8802623 A1 also relates to biomaterials biocompatible surface, taking a variety of starting materials and binding mechanisms including the use of hyaluronic acid for the production of a biocompatible contact lens is disclosed.
  • the object of the present invention is therefore to provide a method for coating stents with a polysaccharide layer, which have an improved adhesion to the substrate surface of the Has the implant and is more functional in its provision Stents.
  • the basic variants 1 and V of the method according to the invention provide the covalent attachment of the non-cross-linked polysaccharide for one significant increase in the adherence of the polysaccharide layer what is experimentally detectable.
  • the further layer can be considered as not cross-linked Polysaccharide applied and then cross-linked or applied directly as cross-linked polysaccharide.
  • a particularly suitable polysaccharide for use in the invention is the already mentioned hyaluronic acid, which can be applied to a wide variety of substrate surfaces of implants can.
  • Alloplastic vascular wall supports - so-called “stents” - are usually coated with amorphous silicon carbide (a-SiC: H), which with Hyaluronic acid forms a particularly intimate and strong bond.
  • a-SiC amorphous silicon carbide
  • the method according to the invention is based on the coating of a Described substrate surface made of amorphous silicon carbide, for example on a stent with a basic structure made of a tantalum alloy is applied.
  • Basic principles of the activation of the silicon carbide substrate surface are DE 195 33682 A1 of the applicant Removable, the attachment and immobilization of heparin on a Silicon carbide coating disclosed.
  • the substrate surface is rinsed with water and incubated in a 20 ⁇ 10 -6 molar Fmoc-p-Bz-Phe-OH solution in N, N'-dimethylformamide (DMF).
  • the Fmoc-p-Bz-Phe-OH solution which acts as a photoactive spacer substance, can be obtained as a commercially available product "Fmoc-p-Bz-Phe-OH", product number B 2220 from "Bachem Biochemica GmbH", Heidelberg.
  • the reduction of the benzophenone is initiated by irradiation with UV light. After the UV irradiation, the reaction solution is poured off and the substrate surface is rinsed several times with distilled water.
  • the next step involves splitting off the Fmoc protecting group 25% piperidine solution in DMF. On the now exposed and responsive Amino group binds the hyaluronic acid. This will be first non-cross-linked hyaluronic acid covalently to that treated Tied substrate surface. The polysaccharide layer thus formed can then be cross-linked.
  • a silanized benzophenone in particular 4- (3'-chlorodimethylsilyl) propyloxybenzophenone
  • an organic solvent such as toluene
  • Et 3 N as a catalyst
  • the substrates are rinsed in chloroform and then in methanol.
  • the layer system substrate-spacer is then wetted with a 0.1% -2% aqueous hyaluronic acid solution and then dried.
  • the hyaluronic acid is covalently bound to the present benzophenone under the action of UV radiation at a wavelength of 340 nm, which initiates the reduction of the benzophenone.
  • the photochemical reaction can also be carried out in aqueous Hyaluronic acid solution can be performed.
  • This photochemical reaction leads to a covalent bond between the benzophenone and a C-H group the polymer chain, especially hyaluronic acid. This to the Substrate surface covalently attached polysaccharide layer can then cross-linked.
  • Chitosan can be incubated in a 0.2% Chitosan solution in a 1-2% acetic acid solution at 65 ° C for 1 h be bound.
  • the stents are then deionized Rinsed water and then dried. This to the substrate surface covalently linked polysaccharide layer can then be cross-linked become.
  • a covalently linked chitosan layer allows one achieve good detention.
  • the glycosaminoglycan chitosan (Mw: 100,000 to 1,000,000 Daltons) is a chemical multi-stage reaction with the help of a spacer covalently to an amorphous silicon carbide layer (a-SiC: H), that covers the base body of the stent.
  • a-SiC amorphous silicon carbide layer
  • Fmoc-p-BZ-Phe-OH N- (9-Fmoc) -l- (4-benzoyl) -phenylalanine; 2 ml; 10 mmol / l; available from Bachem
  • DMF N'-dimethylformamide
  • the stent is then in a 0.2% solution of chitosan in 1% Acetic acid and N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (50 mg / ml) incubated in ice water for at least 12 hours.
  • the covalent The chitosan is coupled by forming a peptide bond between the activated carboxylic acid of the spacer and the amino group of the Chitosans or formation of an ester bond between the activated Carboxylic acid of the spacer and the hydroxyl group of the chitosan.
  • the sample is rinsed several times with deionized water and then dried.
  • Adhesion promoter serves and for a subsequent covalent attachment of a Polysaccharide layer suitable functional groups on the surface having.
  • Adhesion promoter layer can be Achieve plasma polymerization of N-heptylamine and acetaldehyde.
  • the plasma polymerization takes place with a 40 kHz model plasma system Piko from Diener electronics.
  • Precourser can acetaldehyde, amyl alcohol, allylamine, ethyl acetoacetate or Acrylic acid can be used.
  • the plasma polymerized layers have due to their hydrophilicity, good wetting with hyaluronic acid solutions on. Furthermore, a thin one can be found on the functional surfaces Layer of hyaluronic acid or other polysaccharides with the help of Couple glutaraldehyde, epichlorohydrin, or carbodiimides.
  • the recipient is flushed with oxygen to finally remove residual gas, with continuous evacuation.
  • the sample room is kept for 10 min. rinsed and for the surface activation the plasma is ignited in the presence of a Teflon block.
  • the power of the reactor is approx. 200 W and during the surface treatment there is an oxygen flow of approx. 40 cm 3 / min. maintained. Activation and simultaneous plasma cleaning takes 5-10 minutes.
  • the power is increased to 80 W. regulated down and the Precourser is let into the recipient.
  • the polymerization time is 5 minutes with the aerometer open.
  • Deactivation can result in further surface activation with oxygen done, but then the power is only 80 W with a duration of approx. 30 sec This short surface activation leads to a further one improved wettability of the surfaces.
  • the hyaluronic acid with the help of a water-soluble carbodiimide covalently to the complex substrate-adhesive layer tethered.
  • the covalent connection of the Hyaluronic acid on the acetaldehyde plasma polymer takes place directly with the help a diimidazole or with a polyethyleneimine liner, which is applied by means of reductive amination.
  • the covalent Linking of hyaluronic acid to this substrate-adhesion promoter complex takes place with the help of a water-soluble carbodiimide. This to the Adhesive layer covalently attached polysaccharide layer can then cross-linked.
  • the substrate surface can by derivatized polyhydroxybutyric acid, which is an experimental proven good layer adhesion on silicon carbide and metals has to be functionalized.
  • the functionalization of polyhydroxybutyric acid is carried out by amination.
  • the covalent connection of the Hyaluronic acid to the amino group of the functionalized Polyhydroxybutyric acid (adhesion promoter layer) is made using a water soluble carbodiimide to form a peptide bond.
  • a monolayer of chitosan can be created as follows:
  • the pre-cleaned stent is dried at 75 ° C for 30 minutes in a drying oven.
  • the still warm stent is then incubated for 10 minutes in a silane solution consisting of 3 ml of anhydrous toluene, 20 ⁇ l of 3- [2- (2-aminoethylamino) ethylamino] propyl-trimethoxysilane and 70 ⁇ l of Et 3 N at room temperature with repeated gentle shaking.
  • the stents are then dried at 75 ° C. for 1 hour.
  • the stent is then rinsed with toluene or chloroform and dried again.
  • adipic acid via a solution of 10 mg / ml adipic acid in water to produce functional carbonyl functions on the surface of the implant.
  • the adipic acid is previously activated in THF or DMF with a carbodiimide or diimidazole.
  • the connection of chitosan follows. To do this, the implant is incubated in a 0.2% solution of chitosan in a 1-2% acetic acid solution at room temperature for 1-4 hours. This is followed by rinsing with deionized water and drying.
  • Hyaluronic acid can be crosslinked with glutaraldehyde as follows:
  • the implant is coated with a 0.1-2% hyaluronic acid solution and then exposed to a crosslinker solution for several hours.
  • the crosslinker solution consists of 240 ml acetone, 80 ml glutaraldehyde in 25% solution in water and 1.6 ml HCL 3 M. Then the Crosslinker solution exchanged for a new solution and it will work again incubated at room temperature for several hours.
  • the means Glutaraldehyde cross-linked hyaluronic acid is distilled several times Washed water. Then the sample is in a 0.5-3% strength Solution of the sodium cyanoborohydride for 1 hour at room temperature incubated.
  • the fixer solution is withdrawn and several follow Wash steps in bidistilled water and isotonic saline.
  • Crosslinking of hyaluronic acid with bifunctional aldehydes and Formaldehyde takes place in a process analogous to the crosslinking of hyaluronic acid with glutaraldehyde.
  • 2 g hyaluronic acid are used to crosslink hyaluronic acid with divinyl sulfone in 50 ml of a 0.1 M aqueous NaOH solution to obtain a 2% solution dissolved.
  • the solution is put on ice.
  • 2 ml of divinyl sulfone are added.
  • the emerging Two-phase mixture is stirred on ice for 15 min. After 5 minutes is only another phase to watch.
  • the implants are in this solution dipped and then dried.
  • crosslinking and covalent attachment of the hyaluronic acid is on Layer systems made of amorphous silicon carbide spacer and an amorphous one Silicon carbide spacer polysaccharide monolayer realizable with diimidazole.
  • the implant with attached spacer or with a polysaccharide layer is immersed in an acetone solution containing diimidazole.
  • the substrate-spacer complex or the polysaccharide layer is in the for at least 30 minutes Activated diimidazole-containing acetone solution and then in an aqueous Hyaluronic acid solution dipped or with a hyaluronic acid solution sprayed.
  • the stent is 0.5-1 sec. sprayed at a carrier air pressure of 2-4 bar. Between the spraying steps the stent is 15-30 sec. dried with warm air supply.
  • the OH and NHR groups of polysaccharides are crosslinked with With the help of acid dichlorides or phosphorus oxychloride with the formation of Ester or amide groups and with the release of HCL in the organic Solvent.
  • a derivatization of the coated hyaluronic acid hydrogel on the The implant can also be implemented as follows.
  • a polymer-analogous conversion of hyaluronic acid delays the enzymatic degradation of hyaluronic acid in vivo or stabilizes the hyaluronic acid in the body, as the following application example shows:
  • the degree of sulfation in this polymer-analogous reaction can be varied by the amount of sulfating agent SO 3 * pyridine added, the reaction time and the reaction temperature.
  • Drug loading with suitable pharmaceuticals usually takes place after Crosslinking and fixation of the polysaccharide layer in the swollen state.
  • the active ingredient can be pre-sprayed or dipped the coating or during the coating with the polysaccharide respectively.
  • the active ingredient is usually embedded in Diffusion processes.
  • the active ingredient is immersed in a hyaluronic acid layer, such as it is available according to one of the preceding examples, embedded.
  • the implant is placed in a solution of 15 mg cyclosporin per ml parity ethanol-water mixture immersed.
  • the ratio of 1: 1 of ethanol to water has been chosen to carry out the Diffusion process proven to be surprisingly effective.
  • Other Conditions, especially those with increased ethanol, slow them down Embedding The implant remains depending on the layer thickness and Degree of crosslinking of the polysaccharide layer for at least one hour in the Solution.
  • the implant is then removed and dried. at a coating amount of 0.5 mg hyaluronic acid is on this Amount of cyclosporin that can be stored at least 0.2 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
EP20030090138 2002-05-24 2003-05-13 Procédé de revêtement d'une prothèses endovasculaires avec une couche de polysaccharides et prothèses obtenues par un tel procédé Withdrawn EP1364664A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002123310 DE10223310A1 (de) 2002-05-24 2002-05-24 Verfahren zum Beschichten von Implantaten mit einer Polysaccharid-Lage
DE10223310 2002-05-24

Publications (1)

Publication Number Publication Date
EP1364664A1 true EP1364664A1 (fr) 2003-11-26

Family

ID=29285692

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20030090138 Withdrawn EP1364664A1 (fr) 2002-05-24 2003-05-13 Procédé de revêtement d'une prothèses endovasculaires avec une couche de polysaccharides et prothèses obtenues par un tel procédé

Country Status (5)

Country Link
US (2) US20040091605A1 (fr)
EP (1) EP1364664A1 (fr)
AU (1) AU2003240641A1 (fr)
DE (1) DE10223310A1 (fr)
WO (1) WO2003099348A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328815A1 (de) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Beschichtungssystem für Implantate zur Erhöhung der Gewebsverträglichkeit
EP1980277A1 (fr) * 2007-03-17 2008-10-15 Peter Hildebrandt Produit médical gastro-entérologique, en particulier stent pour voie biliaire et pancréatique
WO2009014916A3 (fr) * 2007-07-20 2010-01-21 Medtronic Vascular Inc. Dispositif médical d'élution de médicament et procédé
EP2113264A3 (fr) * 2008-05-02 2010-03-31 BIOTRONIK VI Patent AG Implant comprenant une surface dotée d'une thrombogénicité réduite
WO2013079476A1 (fr) 2011-11-30 2013-06-06 Bayer Materialscience Ag Appareil médical enduit de produit pharmaceutique et son procédé de fabrication

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
DE10311729A1 (de) * 2003-03-18 2004-09-30 Schultheiss, Heinz-Peter, Prof. Dr. Endovaskuläres Implantat mit einer mindestens abschnittsweisen aktiven Beschichtung aus Ratjadon und/oder einem Ratjadon-Derivat
DE10329296B4 (de) * 2003-06-24 2007-07-12 Leibniz-Institut Für Polymerforschung Dresden E.V. Beschichtungssystem für Biomaterialien
US7488343B2 (en) * 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
US8241655B2 (en) 2004-05-12 2012-08-14 Surmodics, Inc. Coatings for medical articles including natural biodegradable polysaccharides
WO2005118019A1 (fr) * 2004-05-28 2005-12-15 Cook Incorporated Structure support de valvule bioabsorbable implantable
BRPI0419111B8 (pt) 2004-10-06 2021-05-25 Bayco Tech Ltd parafuso de implante ósseo, processo para preparação do mesmo e uso do ácido hialurônico
WO2007035865A1 (fr) * 2005-09-21 2007-03-29 Surmodics, Inc. Occlusion in situ utilisant des polysaccharides biodegradables naturels
CN101309709A (zh) * 2005-09-21 2008-11-19 苏尔莫迪克斯公司 包含天然生物可降解的多糖的涂层和物品
US8858608B2 (en) * 2007-12-10 2014-10-14 Cook Medical Technologies Llc Lubrication apparatus for a delivery and deployment device
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US8936811B2 (en) * 2008-05-07 2015-01-20 Surmodics, Inc. Device coated with glycogen particles comprising nucleic acid complexes
DE102008053892A1 (de) 2008-10-30 2010-05-06 Fachhochschule Gelsenkirchen Medizinisches Implantat mit biofunktionalisierter Oberfläche
US8652505B2 (en) * 2010-03-04 2014-02-18 Southwest Research Institute Coating for medical implants
US9095558B2 (en) 2010-10-08 2015-08-04 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012048283A1 (fr) 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Traitement en une étape d'hydrogels pour obtenir des caractéristiques mécaniquement robustes et chimiquement souhaitables
FR2968305B1 (fr) 2010-12-06 2014-02-28 Teoxane Procede de preparation d'un gel reticule
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
MX2015007410A (es) * 2012-12-11 2015-12-15 Univ Texas Membrana de hidrogel para prevencion de la adhesion.
CN105473622B (zh) * 2013-06-28 2019-01-29 盖尔德玛公司 用于制造成形的交联的透明质酸产物的方法
US10232090B2 (en) 2013-08-23 2019-03-19 Southwest Research Institute Electrophoretically deposited strontium fluoride nanoparticle/polymer coatings for medical implants
WO2018165327A1 (fr) 2017-03-08 2018-09-13 Alafair Biosciences, Inc. Milieu hydrogel pour le stockage et la conservation de tissu

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
WO2000056377A1 (fr) * 1999-03-19 2000-09-28 Genzyme Corporation Modification de surface pour substrats
WO2001041827A1 (fr) * 1999-12-07 2001-06-14 Navid Malik Matieres biomimetiques a support interne et enrobages
WO2002018003A1 (fr) * 2000-08-30 2002-03-07 Biocoat Incorporated Revetements de hyaluronane bi-laminaires a proprietes anti-microbiennes dues a des ions argent
WO2002039948A2 (fr) * 2000-11-14 2002-05-23 N.V.R. Labs Inc. Gels de laminine et d'acide hyaluronique reticule et leur utilisation dans la culture cellulaire et les implants medicaux

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023114A (en) * 1984-08-23 1991-06-11 Gregory Halpern Method of hydrophilic coating of plastics
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5263992A (en) * 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US4979959A (en) * 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
US5356433A (en) * 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
DE69328523T2 (de) * 1992-02-13 2000-09-21 Surmodics, Inc. Immobilisierung eines chemischen spezies in einer vernetzten matrix
IL106922A (en) * 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
JPH08507715A (ja) * 1993-03-18 1996-08-20 シーダーズ サイナイ メディカル センター 生体人工部材のための薬剤導入性および放出性重合性コーティング
US5643580A (en) * 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
DE4444445C2 (de) * 1994-12-14 1998-07-02 Keller Ruprecht Priv Doz Dr Dr Verfahren zur Herstellung gewebeverträglicher Substrate, gewebeverträgliches Substrat und seine Verwendung
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5672638A (en) * 1995-08-22 1997-09-30 Medtronic, Inc. Biocompatability for solid surfaces
DE19533682A1 (de) * 1995-09-12 1997-03-13 Biotronik Mess & Therapieg Verfahren zum Anlagern und Immobilisieren von Heparin auf anorganischen Substratoberflächen von kardiovaskulären Implantanten
US5840046A (en) * 1996-06-21 1998-11-24 Medtronic, Inc. Guidewire having hydrophilic coating
DE19630879A1 (de) * 1996-07-31 1998-02-05 Hanno Lutz Prof Dr Baumann Verfahren zur Herstellung blutverträglicher Werkstoffe durch Oberflächenbeschichtung von synthetischen Polymeren mit wasserlöslichen Substanzen aus natürlichen oder modifizierten Oligo- und Polysacchariden über kovalente Bindungen
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
DE19729279A1 (de) * 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248127B1 (en) * 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6160032A (en) * 1998-09-30 2000-12-12 Medtronic Ave, Inc. Biocompatible coating composition
GB9902652D0 (en) * 1999-02-05 1999-03-31 Fermentech Med Ltd Process
EP1048304A1 (fr) * 1999-04-30 2000-11-02 Novartis AG Revêtements neutre
FR2807326B1 (fr) * 2000-04-10 2002-08-23 Therapeutiques Substitutives Prothese vasculaire impregnee de dextrane reticule et/ou d'un derive fonctionnalise de dextane reticule et son procede de preparation
JP4754714B2 (ja) * 2000-06-01 2011-08-24 テルモ株式会社 管腔内留置物
US6673453B2 (en) * 2001-06-12 2004-01-06 Biocoat Incorporated Coatings appropriate for medical devices
FR2827799A1 (fr) * 2001-07-27 2003-01-31 Sofradim Production Endoprothese vasculaire recouverte d'un derive fonctionnalise de dextrane et son procede de preparation
US6765069B2 (en) * 2001-09-28 2004-07-20 Biosurface Engineering Technologies, Inc. Plasma cross-linked hydrophilic coating
US6706408B2 (en) * 2002-05-16 2004-03-16 Surmodics, Inc. Silane coating composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
WO2000056377A1 (fr) * 1999-03-19 2000-09-28 Genzyme Corporation Modification de surface pour substrats
WO2001041827A1 (fr) * 1999-12-07 2001-06-14 Navid Malik Matieres biomimetiques a support interne et enrobages
WO2002018003A1 (fr) * 2000-08-30 2002-03-07 Biocoat Incorporated Revetements de hyaluronane bi-laminaires a proprietes anti-microbiennes dues a des ions argent
WO2002039948A2 (fr) * 2000-11-14 2002-05-23 N.V.R. Labs Inc. Gels de laminine et d'acide hyaluronique reticule et leur utilisation dans la culture cellulaire et les implants medicaux

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328815A1 (de) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Beschichtungssystem für Implantate zur Erhöhung der Gewebsverträglichkeit
EP1980277A1 (fr) * 2007-03-17 2008-10-15 Peter Hildebrandt Produit médical gastro-entérologique, en particulier stent pour voie biliaire et pancréatique
WO2009014916A3 (fr) * 2007-07-20 2010-01-21 Medtronic Vascular Inc. Dispositif médical d'élution de médicament et procédé
US8070798B2 (en) 2007-07-20 2011-12-06 Josiah Wilcox Drug eluting medical device and method
EP2113264A3 (fr) * 2008-05-02 2010-03-31 BIOTRONIK VI Patent AG Implant comprenant une surface dotée d'une thrombogénicité réduite
WO2013079476A1 (fr) 2011-11-30 2013-06-06 Bayer Materialscience Ag Appareil médical enduit de produit pharmaceutique et son procédé de fabrication

Also Published As

Publication number Publication date
DE10223310A1 (de) 2003-12-11
US20070026038A1 (en) 2007-02-01
US20040091605A1 (en) 2004-05-13
US8173196B2 (en) 2012-05-08
WO2003099348A1 (fr) 2003-12-04
AU2003240641A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
EP1364664A1 (fr) Procédé de revêtement d'une prothèses endovasculaires avec une couche de polysaccharides et prothèses obtenues par un tel procédé
DE69231155T2 (de) Mit arzneimittel überzogenes lichtbrechendes implantat für die vordere augenkammer
DE3856430T2 (de) Herstellung von polymeren oberflächen
EP1886702B1 (fr) Implant en matière première métallique biocorrodable doté d'un revêtement en alliage d'organosilicium
US7125860B1 (en) Cross-linked derivatives of hyaluronic acid
DE60223589T2 (de) Verfahren zum modifizieren der oberfläche von biomedizinischen gegenständen
EP1858438B1 (fr) Revetements polymeres elastiques pour articles medicaux inserables
DE60310540T2 (de) Polymerbeschichtung für medizinische vorrichtungen
EP1220694B1 (fr) Appareil medical recouvert de fibres de polyethylenimine lineaire modifiees avec l'oxyde nitrique et methode pour sa fabrication
DE60026065T2 (de) Elektropolymerisierbare monomere und polymerbeschichtungen auf implantierbaren geräten
DE69733831T2 (de) Medizinische geräte mit beschichtung aus durch hydrophilespacergruppen gebundenem bioaktiven material
DE69811666T2 (de) Behandlung metallischer oberflächen zur verbesserung ihrer bioverträglichkeit und/oder ihrer physikalischen eigenschaften
EP1952831B1 (fr) Stents revêtus de biomolécules et leur procédé de fabrication
AU2009290833B2 (en) Immobilised biological entities
JP2001500408A (ja) 共有結合ヘパリンを含む表面コーティングを介した有意な開通性強化を有するePTFE小直径血管移植片
EP2454286A1 (fr) Dérivés d hydrogel de chitosane utilisés comme agent de revêtement à activité antimicrobienne à large spectre
WO2019034207A2 (fr) Procédé de réalisation d'une couche biocompatible sur une surface d'implant
EP2106812A2 (fr) Procédés de fabrication et d'utilisation de polymères tensioactifs
EP1644054B1 (fr) Systeme de revetement pour implants destine a augmenter la compatibilite avec des tissus
EP3153186B1 (fr) Procede de fabrication d'une composition de revetement antibacterienne pour implants
DE19849464A1 (de) Wirkstofffreisetzende Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
WO2003086496A1 (fr) Implant medical, de preference stent, et procede de fabrication dudit stent
JPH05300940A (ja) 表面潤滑性付与剤
JPH02144070A (ja) 易滑性医療材料
EP1814919B1 (fr) Procede de production de structures planes multicouches, de particules, ou de fibres

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20040113

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOTRONIK GMBH & CO. KG

17Q First examination report despatched

Effective date: 20090114

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOTRONIK SE & CO. KG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOTRONIK SE & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110806